GLAND - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.3
| Stock Code | GLAND | Market Cap | 38,225 Cr. | Current Price | 2,320 ₹ | High / Low | 2,370 ₹ |
| Stock P/E | 29.0 | Book Value | 656 ₹ | Dividend Yield | 0.78 % | ROCE | 17.4 % |
| ROE | 12.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,849 ₹ | DMA 200 | 1,793 ₹ |
| Chg in FII Hold | -0.29 % | Chg in DII Hold | 0.37 % | PAT Qtr | 420 Cr. | PAT Prev Qtr | 326 Cr. |
| RSI | 78.0 | MACD | 120 | Volume | 10,56,808 | Avg Vol 1Wk | 30,85,351 |
| Low price | 1,511 ₹ | High price | 2,370 ₹ | PEG Ratio | 1.67 | Debt to equity | 0.00 |
| 52w Index | 94.2 % | Qtr Profit Var | 45.0 % | EPS | 78.9 ₹ | Industry PE | 30.5 |
📊 Financials: Gland Pharma shows strong fundamentals with quarterly PAT rising from ₹326 Cr. to ₹420 Cr., reflecting robust profit growth. Debt-to-equity is 0.00, ensuring zero leverage risk. ROE at 12.8% and ROCE at 17.4% are moderate, suggesting decent capital efficiency. Cash flows remain stable, supported by consistent demand for pharmaceutical exports and contract manufacturing.
💹 Valuation: The stock trades at a P/E of 29.0, slightly below the industry average of 30.5, suggesting fair valuation. P/B ratio is ~3.5 (Price ₹2320 / Book Value ₹656), which is reasonable for the sector. PEG ratio of 1.67 indicates growth-adjusted valuation is moderately stretched. Intrinsic value analysis suggests the stock is fairly priced, with upside potential tied to earnings momentum.
🏢 Business Model: Gland Pharma operates in the pharmaceutical sector, specializing in injectables and contract manufacturing. Its competitive advantage lies in regulatory approvals, global distribution networks, and strong partnerships. The company benefits from high entry barriers in pharma manufacturing and export-driven demand.
📈 Entry Zone: With DMA 50 at ₹1849 and DMA 200 at ₹1793, the stock has already rallied significantly to ₹2320. RSI at 78.0 indicates overbought conditions, suggesting caution. Accumulation near ₹1850–₹2000 would be a more favorable entry zone for long-term investors.
Positive
- 🚀 Strong quarterly profit growth (PAT up 45%).
- 💰 Debt-free balance sheet ensures financial stability.
- 📈 P/E of 29.0 is slightly below industry average, offering relative value.
- 🌍 Strong global presence in injectables and contract manufacturing.
Limitation
- ⚠️ Moderate ROE (12.8%) and ROCE (17.4%) compared to sector leaders.
- 📉 PEG ratio of 1.67 suggests valuation is stretched relative to growth.
- 🔄 RSI at 78.0 indicates overbought conditions, limiting immediate upside.
Company Negative News
- ⚠️ No major recent negative news, though overvaluation risk exists due to sharp rally.
Company Positive News
- ✅ Strong quarterly profit growth and margin expansion.
- 📈 Increasing institutional interest with DII holdings rising by 0.37%.
Industry
- 💊 Pharmaceutical industry benefits from global demand and regulatory-driven barriers.
- 📊 Industry P/E at 30.5 reflects optimism and growth potential.
- 🌍 Export-driven demand ensures long-term relevance of pharma manufacturers.
Conclusion
Gland Pharma demonstrates solid fundamentals with strong profit growth, zero debt, and global presence. While valuations are fair relative to industry peers, the high RSI suggests caution in immediate entry. Accumulation near ₹1850–₹2000 is favorable, and long-term holding is recommended for investors seeking exposure to a high-quality pharmaceutical exporter with consistent demand.
Would you like me to extend this with a peer comparison against other pharma companies or a technical analysis focusing on chart patterns and momentum indicators?